2) ErbB family
上皮生长因子受体家族
3) Epidermal growth factor family
表皮生长因子家族
5) Epidermal growth factor (EGF)/Epidermal growth factor receptor (EGFR)
表皮生长因子/表皮生长因子受体
6) epidermal growth factor receptor (EGFR)
表皮生长因子受体
1.
Somatic mutation in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene is associated with the sensitivity of non-smal cell lung cancer (NSCLC) to TK inhibitor Gefitinib.
表皮生长因子受体(EGFR)基因酪氨酸激酶域体细胞突变与非小细胞肺癌(NSCLC)患者对酪氨酸激酶抑制剂吉非替尼敏感性密切相关。
2.
The epidermal growth factor receptor (EGFR) provides a rational target for cancer therapy as it is commonly overexpressed in a variety of solid tumors, and its deregulation is correlated with resistance to chemotherapy and radiotherapy and a poor prognosis.
在许多肿瘤组织中均有表皮生长因子受体(epidermal growthfactor receptor,EGFR)的过表达,它的失调与肿瘤对化疗和放疗的耐受以及不良预后相关,为肿瘤的治疗提供了一个理想的分子靶点。
3.
The overexpression and inappropriate activation of epidermal growth factor receptor (EGFR) is thought to play an important role in many tumors, especially for the head and neck carcinomas with the overexpression rate of 80%—100%.
表皮生长因子受体(Epidermal Growth Factor Receptor，EGFR)的过度表达和不恰当激活被认为与多种肿瘤的发生发展密切相关，尤其在头颈部肿瘤中EGFR表达上调最普遍，约占80％-100％。
补充资料：表皮生长因子受体
表皮生长因子受体
为膜受体酪氨酸激酶，因其上有受体分子而表现酶的活性。对其形成的调节机制尚不清楚。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条